Filing Analysis
Prelude Therapeutics Inc. filed an 8-K to announce its financial results for the three months ended June 30, 2026. The filing serves as a formal notification of the release of quarterly earnings data.
📋 Key Facts
- Report date: August 11, 2026
- Reporting period: Three months ended June 30, 2026
- The filing includes Exhibit 99.1 containing the press release of financial results.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 of the Exchange Act.
Prelude Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders approved the election of three Class III Directors, the ratification of Ernst & Young LLP as the independent auditor, and advisory votes regarding executive compensation.
📋 Key Facts
- Election of Class III Directors Krishna Vaddi, Paul Scherer, and Katina Dorton for three-year terms expiring in 2029.
- Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Approval of 2025 executive compensation with 26,869,142 shares voting 'For'.
- Approval of a 1-year frequency for advisory votes on executive compensation with 26,877,941 shares voting 'For'.
Prelude Therapeutics reported its financial results for the first quarter ended March 31, 2026, and released an updated investor presentation. The filing serves as a routine quarterly update for investors.
📋 Key Facts
- Announced financial results for the three months ended March 31, 2026, on May 12, 2026
- Furnished a press release as Exhibit 99.1
- Provided an updated investor presentation as Exhibit 99.2
- Reported under Items 2.02 (Results of Operations) and 7.01 (Regulation FD Disclosure)
Prelude Therapeutics announced a $85.5 million securities offering consisting of common stock and pre-funded warrants. The capital raise, led by RA Capital Management, is intended to fund clinical development and extend the company's cash runway into the second quarter of 2028.
🚩 Red Flags
- Significant dilution of existing shareholders through the issuance of over 20 million new shares/equivalents.
📋 Key Facts
- Agreement to sell 18,018,014 shares of common stock at $4.44 per share.
- Agreement to sell 2,252,252 pre-funded warrants at $4.4399 per warrant with a $0.0001 exercise price.
- Estimated net proceeds of approximately $85.5 million after fees and expenses.
- Offering led by RA Capital Management with participation from Soleus Capital.
- Company expects existing cash plus offering proceeds to fund operations into Q2 2028.
- Underwriters include Goldman Sachs & Co. LLC and Evercore Group L.L.C.
Prelude Therapeutics announced positive preclinical data for its lead development candidate PRT13722, a first-in-class KAT6A degrader, at the AACR Annual Meeting 2026. The company remains on track to file an Investigational New Drug (IND) application in mid-2026.
📋 Key Facts
- PRT13722 is a first-in-class, orally bioavailable, potent and highly selective KAT6A degrader.
- Preclinical data showed durable complete tumor regressions in HR+/HER2- breast cancer xenograft models as a monotherapy.
- The candidate demonstrated synergy with endocrine therapy, CDK4/6 inhibitors, and PI3Kα inhibitors.
- PRT13722 showed an improved preclinical hematological safety profile compared to prifetrastat.
- IND filing is targeted for mid-2026 with Phase 1 initiation anticipated in H2 2026.
Prelude Therapeutics Incorporated has appointed Dr. Charles Q. Morris as its new Chief Medical Officer, effective April 20, 2026. Dr. Morris brings significant industry experience from previous CMO roles at Lava Therapeutics, Celyad Oncology, and Radius Health.
📋 Key Facts
- Dr. Charles Q. Morris appointed as Chief Medical Officer effective April 20, 2026.
- Initial annual base salary set at $535,000 with a discretionary bonus target of 40%.
- Granted an option to purchase 450,000 shares of common stock, vesting over four years.
- Dr. Morris previously served as CMO at Lava Therapeutics N.V. until its acquisition by XOMA Royalty in October 2025.
- Severance terms include 9 months of base salary and healthcare, or 12 months plus 100% equity acceleration if terminated following a change in control.
Prelude Therapeutics filed a prospectus supplement to sell up to $25.0 million of common stock through an 'at-the-market' (ATM) offering facility with Jefferies LLC. This offering is part of a previously established $75.0 million sales agreement and utilizes the company's existing shelf registration statement.
🚩 Red Flags
- Potential shareholder dilution resulting from the issuance of up to $25.0 million in new common stock.
📋 Key Facts
- The company filed a prospectus supplement on March 12, 2026, to sell up to $25.0 million of common stock.
- Jefferies LLC is acting as the sales agent for the offering.
- The offering utilizes an existing Shelf Registration Statement on Form S-3 (File No. 333-279829) declared effective on June 10, 2024.
- The underlying Open Market Sale Agreement with Jefferies was originally entered into on March 15, 2023, for up to $75.0 million.
Prelude Therapeutics announced its full-year 2025 financial results and released an updated investor presentation on March 10, 2026.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2025
- Furnished a press release as Exhibit 99.1 on March 10, 2026
- Released updated investor presentation materials as Exhibit 99.2
- The report was signed by Bryant Lim, Chief Financial Officer and Chief Legal Officer
Prelude Therapeutics announced that the FDA has cleared a Phase 1 study for its mutant-selective JAK2V617F inhibitor, PRT12396. This development marks a clinical milestone in the company's oncology pipeline for treating myeloproliferative neoplasms.
📋 Key Facts
- FDA clearance received for a Phase 1 study under an Investigational New Drug (IND) application.
- The drug candidate is PRT12396, a mutant-selective JAK2V617F inhibitor.
- Target indication: treatment of patients with certain myeloproliferative neoplasms.
Prelude Therapeutics filed an 8-K to furnish investor presentation materials being used for management presentations starting January 9, 2026. The filing is made pursuant to Item 7.01 (Regulation FD Disclosure) and the information is furnished but not considered 'filed' for liability purposes.
📋 Key Facts
- The company prepared investor presentation materials as of January 9, 2026.
- Materials are attached as Exhibit 99.1.
- Information is being furnished under Item 7.01 (Regulation FD Disclosure).
- Management intends to use these materials for presentations commencing on the date of the filing.
Prelude Therapeutics announced its quarterly financial results for the period ending September 30, 2025. The filing includes a press release of the earnings and investor presentation materials.
📋 Key Facts
- Reported financial results for the three months ended September 30, 2025.
- Issued an investor presentation (Exhibit 99.2) to be used by management in upcoming presentations.
- Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Prelude Therapeutics entered into an exclusive option agreement with Incyte Corporation to potentially sell its JAK2V617F inhibitor program for up to $910 million in total consideration. The deal includes an immediate $35 million cash infusion and a $25 million equity investment from Incyte.
🚩 Red Flags
- Officer Departure: Resignation of the President and Chief Medical Officer (Jane Huang), though she remains as a consultant.
- Strategic Pivot/Program Pause: The company is pausing its SMARCA2 degrader program, indicating a narrowing of focus or resource reallocation.
📋 Key Facts
- Incyte has an exclusive option to acquire the JAK2V617F JH2 inhibitor program for $100 million upon exercise of the option.
- Total potential deal value is up to $910 million, including $775 million in clinical/regulatory milestones and royalties.
- Immediate capital inflow: $35 million cash + $25 million equity investment from Incyte.
- Incyte is purchasing 6,250,000 shares of non-voting common stock at $4.00 per share ($25 million total).
- The company will register these shares on a Form S-3 Resale Registration Shelf.
- Dr. Jane Huang resigned as President and CMO effective Nov 3, 2025, transitioning to a consulting role through Sept 15, 2026.
Prelude Therapeutics announced a change in its Board of Directors involving the resignation of Mardi Dier and the appointment of Katina Dorton. Ms. Dorton will serve as a Class III director and Chair of the Audit Committee.
🚩 Red Flags
- None identified; the resignation was explicitly stated as not being due to any disagreement regarding operations, policies, or practices.
📋 Key Facts
- Mardi Dier resigned from the Board effective October 17, 2025; her departure was not due to any disagreement with the Company.
- Katina Dorton appointed as Class III director and Audit Committee Chair effective October 17, 2025.
- Ms. Dorton brings over 30 years of finance/healthcare experience, including roles at Morgan Stanley, Needham & Company, and CFO of NodThera.
- Ms. Dorton granted non-incentive stock options to purchase up to 76,000 shares of common stock, vesting over three years.
- The company will enter into an indemnity agreement with Ms. Dorton.
Prelude Therapeutics has successfully regained compliance with the Nasdaq Minimum Bid Price Requirement. This resolves a deficiency notice originally issued on March 27, 2025, regarding the company's stock price falling below $1.00.
🚩 Red Flags
- Historical non-compliance with Nasdaq listing rules (though currently resolved).
📋 Key Facts
- The Company was previously non-compliant with Nasdaq Listing Rule 5550(a)(2) due to failing the $1.00 Minimum Bid Price Requirement.
- Nasdaq notified the Company on September 18, 2025, that it has regained compliance.
- The matter regarding the minimum bid price deficiency is now considered closed by Nasdaq.
Prelude Therapeutics Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2025 and provided updated investor presentation materials.
📋 Key Facts
- Reported financial results for the three months ended June 30, 2025 via press release (Exhibit 99.1).
- Released new investor presentation materials (Exhibit 99.2) for use by management in upcoming presentations.
- Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Prelude Therapeutics announced the appointment of Paul Scherer, M.D., to its Board of Directors and reported the results of its 2025 Annual Meeting of Stockholders. The meeting resulted in the election of two directors and the ratification of Ernst & Young LLP as the company's independent auditor.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Paul Scherer, M.D., appointed as a Class III director, member of the Compensation Committee, and Governance Committee effective June 12, 2025.
- Dr. Scherer granted non-incentive stock options to purchase up to 76,000 shares of common stock under the 2020 Equity Incentive Plan.
- Martin Babler and Victor Sandor, M.D.C.M., were elected as Class II Directors for three-year terms expiring in 2028.
- Shareholders ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025.
- Shareholders approved an amendment to increase authorized non-voting common stock from 12,850,259 to 112,850,259 shares.
Prelude Therapeutics Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2025 and provided updated investor presentation materials.
📋 Key Facts
- Announced financial results for the three months ended March 31, 2025 via press release (Exhibit 99.1).
- Released new investor presentation materials (Exhibit 99.2) to be used by management in upcoming presentations.
- The filing was signed by Bryant Lim, Chief Legal Officer, Corporate Secretary, and CFO.
Prelude Therapeutics announced the presentation of new preclinical data for its IV SMARCA2 and KAT6A degraders at the AACR Annual Meeting. The filing serves as a formal announcement of scientific progress rather than a material financial or structural change.
📋 Key Facts
- Company presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting on April 25, 2025.
- Data focused on two specific assets: a highly selective IV SMARCA2 degrader and a highly selective KAT6A degrader.
Prelude Therapeutics received a Bid Price Notice from Nasdaq stating the company is in violation of the $1.00 minimum bid price requirement. The company has an initial 180-day window to regain compliance by September 23, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential for mandatory reverse stock split to regain compliance
- Failure to maintain minimum bid price requirement
📋 Key Facts
- Received Bid Price Notice from Nasdaq Listing Qualifications staff on March 27, 2025.
- Violation of Nasdaq Listing Rule 5550(a)(2) due to closing bid price being below $1.00 for the prior 30 consecutive business days.
- Initial compliance period granted until September 23, 2025.
- To regain compliance, stock must close at or above $1.00 for at least ten consecutive business days during the 180-day window.
- A second 180-day grace period may be available if a reverse stock split is utilized to cure the deficiency.
Prelude Therapeutics Inc. has filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024, and provided updated investor presentation materials.
📋 Key Facts
- Report date: March 10, 2025
- Announced full-year 2024 financial results via press release (Exhibit 99.1).
- Released new investor presentation materials for management use (Exhibit 99.2).
- The filing is furnished but not 'filed' under Section 18 of the Exchange Act.
Prelude Therapeutics has appointed Bryant D. Lim as the permanent Chief Financial Officer, effective February 3, 2025. Mr. Lim, who was previously serving in an interim capacity while maintaining his roles as Chief Legal Officer and Corporate Secretary, will now hold both positions permanently.
🚩 Red Flags
- Dual role (CFO and CLO) can sometimes indicate resource constraints or lack of specialized oversight in mid-cap companies, though common in smaller biotech firms.
📋 Key Facts
- Effective Date: February 3, 2025.
- Appointment: Bryant D. Lim appointed permanent CFO (previously interim).
- Dual Role: Mr. Lim continues to serve as Chief Legal Officer and Corporate Secretary.
- Compensation: Base annual salary of $483,000 with a discretionary bonus up to 40% of base salary.
- Equity Incentive: Option to purchase 200,000 shares of common stock with a 4-year monthly vesting schedule after a 1-year cliff.
Prelude Therapeutics announced the presentation of first interim clinical data for its CDK9 inhibitor, PRT2527, at the 66th American Society of Hematology Annual Meeting. The data covers monotherapy and combination therapy with zanubrutinib in patients with relapsed/refractory lymphoid malignancies.
📋 Key Facts
- Presentation of first interim clinical data for PRT2527 (CDK9 inhibitor).
- Trial design: Open-label, dose-escalation trial.
- Study arms: Monotherapy and combination with zanubrutinib.
- Patient population: Relapsed/refractory lymphoid malignancies.
- Event: 66th American Society of Hematology Annual Meeting in San Diego.
Prelude Therapeutics announced its financial results for the third quarter ended September 30, 2024. The filing includes a press release and investor presentation materials.
📋 Key Facts
- Report date: November 6, 2024
- Reporting period: Three months ended September 30, 2024
- Includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Investor Presentation)
- The information is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Prelude Therapeutics issued an 8-K to announce updated interim clinical data from its Phase 1 trial of PRT3789 and preclinical data regarding its precision degrader antibody conjugate program. The announcement coincided with a presentation at the EORTC-NCI-AACR Symposium.
📋 Key Facts
- Updated interim clinical data released for Phase 1 trial of PRT3789 on October 24, 2024.
- Preclinical data presented for precision degrader antibody conjugate program using a novel SMARCA2/4 dual degrader payload.
- Data was presented at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain.
Prelude Therapeutics announced interim clinical data from its Phase 1 trial of PRT3789, a SMARCA2 degrader, presented at the ESMO Congress 2024. The company also held an investor webcast and updated its corporate presentation to reflect these developments.
📋 Key Facts
- Announced first interim clinical data from Phase 1 open-label, dose-escalation trial of PRT3789.
- PRT3789 is a novel, highly-selective SMARCA2 degrader.
- Data was presented at the European Society of Medical Oncology (ESMO) Congress 2024.
- Held an investor webcast on September 13, 2024.
- Updated corporate presentation released via Exhibit 99.3.
Prelude Therapeutics announced the publication of a scientific abstract regarding its SMARCA2 degrader (PRT3789) at the ESMO Congress 2024. The company will provide an oral presentation and host an investor webcast on September 13, 2024.
📋 Key Facts
- Publication of abstract for PRT3789, a novel SMARCA2 degrader, at ESMO Congress 2024.
- Oral presentation scheduled for September 13, 2024, at 10:00 a.m. EST.
- Investor webcast scheduled for September 13, 2024, at 12:00 p.m. EST.
Prelude Therapeutics announced its quarterly financial results for the period ending June 30, 2024. The filing includes a press release of earnings and updated investor presentation materials.
📋 Key Facts
- Reported financial results for the three months ended June 30, 2024.
- Issued an updated investor presentation (Exhibit 99.2) to be used by management in upcoming presentations.
- Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Prelude Therapeutics held its 2024 Annual Meeting of Stockholders on June 14, 2024. The meeting resulted in the successful election of two Class I Directors and the ratification of Ernst & Young LLP as the company's independent auditor for the upcoming fiscal year.
📋 Key Facts
- Annual Meeting held on June 14, 2024.
- Paul A. Friedman, M.D., elected to a three-year term expiring in 2027 (31,165,370 shares for).
- David P. Bonita, M.D., elected to a three-year term expiring in 2027 (31,007,172 shares for).
- Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2024 (34,994,229 shares for).
Prelude Therapeutics filed an 8-K to provide a corporate presentation and announce the release of an educational video series regarding SMARCA degraders. The filing is primarily for investor relations purposes under Regulation FD.
📋 Key Facts
- Company released a new corporate presentation (Exhibit 99.1).
- Company announced an educational video series on SMARCA degraders to be hosted on their Investor Relations website.
- The filing is furnished under Item 7.01 (Regulation FD Disclosure) and not 'filed' for purposes of Section 18 liability.
This is an amendment to a previous 8-K filing regarding the appointment of Bryant D. Lim as Interim Chief Financial Officer. The amendment specifically discloses the compensatory arrangement (stock options) approved for Mr. Lim.
🚩 Red Flags
- Interim status of the CFO appointment may indicate sudden turnover or transition in financial leadership.
📋 Key Facts
- Bryant D. Lim appointed as Interim Chief Financial Officer.
- Grant Date for compensation: May 14, 2024.
- Compensation includes stock options to purchase up to 25,000 shares of common stock.
- Exercise price set at $3.86 per share.
- Vesting schedule: 4-year term with a 1-year cliff (25% vesting after one year) and monthly thereafter.
Prelude Therapeutics Inc. filed an 8-K to announce its quarterly financial results for the three months ended March 31, 2024.
📋 Key Facts
- Report date: May 7, 2024
- Reporting period: Three months ended March 31, 2024
- The filing is a standard earnings announcement via press release (Exhibit 99.1)
- Information is furnished but not filed for purposes of Section 18 of the Exchange Act
Prelude Therapeutics announced the departure of Chief Financial Officer Laurent Chardonnet effective April 8, 2024. The company has appointed its current Chief Legal Officer, Bryant D. Lim, to serve as interim CFO while a permanent replacement is sought.
🚩 Red Flags
- Sudden departure of a key C-suite executive (CFO).
📋 Key Facts
- Laurent Chardonnet departed as CFO on April 8, 2024.
- Chardonnet will provide consulting services at $500/hour until October 4, 2024.
- Severance package includes nine months of base salary ($333,750) and nine months of subsidized COBRA coverage.
- Bryant D. Lim (current CLO and Corporate Secretary) appointed as interim CFO, Principal Financial Officer, and Principal Accounting Officer.
- Chardonnet's outstanding equity awards will continue to vest through the consulting period.
Prelude Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the release of their annual earnings press release.
📋 Key Facts
- Report date: February 15, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1, which contains the full press release of financial results.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 of the Exchange Act.